Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial with a recombinant humanized anti-CD33 monoclonal antibody (HuM195) [lintuzumab] in patients with high risk primary myelodysplastic syndromes.

Next Previous
X
Search
Trial Profile

Phase II trial with a recombinant humanized anti-CD33 monoclonal antibody (HuM195) [lintuzumab] in patients with high risk primary myelodysplastic syndromes.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lintuzumab (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jul 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Jul 2008 Planned patient number is 25 as reported by ClinicalTrials.gov.
    • 02 May 2007 Updated from CT.gov, DMS changes 13/2/07

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top